Annesofie Faurschou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Annesofie Faurschou has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Hans Christian Wulf
4 shared publications- Robert Gniadecki
Division of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
3 shared publications - Anders W. Jørgensen
The Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark
1 shared publication - Britta Tendal
Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark
1 shared publication - Claus Zachariae
Department of Dermatology and Allergy Herlev and Gentofte Hospital Gentofte Denmark
1 shared publication Damien Calay
Department of Dermatology, University of Copenhagen, Bispebjerg Hospital, Copenhagen, Denmark
1 shared publication
Latest Publications
- 8 October 2010
- Published by Springer Nature
- p. 125-146
Photoepilation of Unwanted Hair Growth
- 1 January 2010
- Published by Springer Nature
- p. 205-210
Dermabrasion, Laser Resurfacing, and Photorejuvenation for Prevention of Non-Melanoma Skin Cancer
- 1 January 2010
- Published by Springer Nature
- p. 205-210
Dermabrasion, Laser Resurfacing, and Photorejuvenation for Prevention of Non-Melanoma Skin Cancer
- 1 February 2009
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 160 (2) , 359-364
Pulsed dye laser vs. intense pulsed light for port-wine stains: a randomized side-by-side trial with blinded response evaluation
Pulsed dye lasers (PDLs) are considered the treatment of choice for port-wine stains (PWS). Studies have suggested broadband intense pulsed light (IPL) to be efficient as well. So far, no studies have directly compared the PDL with IPL in a randomized clinical trial. To compare efficacy and adverse events of PDL and IPL in an intraindividual randomized clinical trial. Twenty patients with PWS (face, trunk, extremities; pink, red and purple colours; skin types I-III) received one side-by-side treatment with PDL (V-beam Perfecta, 595 nm, 0.45-1.5 ms; Candela Laser Corporation, Wayland, MA, U.S.A.) and IPL (StarLux, Lux G prototype handpiece, 500-670 and 870-1400 nm, 5-10 ms; Palomar Medical Technologies, Burlington, MA, U.S.A.). Settings depended on the preoperative lesional colour. Treatment outcome was evaluated by blinded, clinical evaluations and by skin reflectance measurements. Both PDL and IPL lightened PWS. Median clinical improvements were significantly better for PDL (65%) than IPL (30%) (P = 0.0004). A higher proportion of patients obtained good or excellent clearance rates with the PDL (75%) compared with IPL (30%) (P = 0.0104). Skin reflectance also documented better results after PDL (33% lightening) than IPL (12% lightening) (P = 0.002). Eighteen of 20 patients preferred to receive continued treatments with PDL (P = 0.0004). No adverse events were observed with PDL or IPL. Both the specific PDL and IPL types of equipment used in this study lightened PWS and both were safe with no adverse events. However, the PDL conveyed the advantages of better efficacy and higher patient preference.
- 1 February 2009
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 160 (2) , 359-364
Pulsed dye laser vs. intense pulsed light for port-wine stains: a randomized side-by-side trial with blinded response evaluation
Pulsed dye lasers (PDLs) are considered the treatment of choice for port-wine stains (PWS). Studies have suggested broadband intense pulsed light (IPL) to be efficient as well. So far, no studies have directly compared the PDL with IPL in a randomized clinical trial. To compare efficacy and adverse events of PDL and IPL in an intraindividual randomized clinical trial. Twenty patients with PWS (face, trunk, extremities; pink, red and purple colours; skin types I-III) received one side-by-side treatment with PDL (V-beam Perfecta, 595 nm, 0.45-1.5 ms; Candela Laser Corporation, Wayland, MA, U.S.A.) and IPL (StarLux, Lux G prototype handpiece, 500-670 and 870-1400 nm, 5-10 ms; Palomar Medical Technologies, Burlington, MA, U.S.A.). Settings depended on the preoperative lesional colour. Treatment outcome was evaluated by blinded, clinical evaluations and by skin reflectance measurements. Both PDL and IPL lightened PWS. Median clinical improvements were significantly better for PDL (65%) than IPL (30%) (P = 0.0004). A higher proportion of patients obtained good or excellent clearance rates with the PDL (75%) compared with IPL (30%) (P = 0.0104). Skin reflectance also documented better results after PDL (33% lightening) than IPL (12% lightening) (P = 0.002). Eighteen of 20 patients preferred to receive continued treatments with PDL (P = 0.0004). No adverse events were observed with PDL or IPL. Both the specific PDL and IPL types of equipment used in this study lightened PWS and both were safe with no adverse events. However, the PDL conveyed the advantages of better efficacy and higher patient preference.
- 11 November 2008
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 24 (6) , 296-300
Sun protection factor persistence during a day with physical activity and bathing
Background/purpose: The persistence of sunscreens during a day with physical activity and bathing is often debated. We wished to examine the durability of the protection achieved by one sunscreen application.Methods: Seven areas were marked on the back of 24 volunteers. One area was phototested to determine UV sensitivity. Six areas were treated with either an organic or an inorganic sunscreen (2 mg/cm2). The participants performed physical activities, were exposed to a hot environment and bathing during 8 h and were phototested with ultraviolet‐B (UVB) radiation 30 min, 4 and 8 h after sunscreen application. The minimal erythema dose (MED) was determined 24 h after irradiation. The sun protection factor (SPF) was calculated, as MED on protected skin/MED on unprotected skin.Results: The SPFs of the inorganic and organic sunscreen, respectively, were reduced by 38% and 41% after 4 h and by 55% and 58% after 8 h.Conclusion: One application of either an inorganic or an organic sunscreen reduced the erythema caused by UVB during a day with physical activity and bathing. After 8 h the sunscreens still provided approximately 43% of the initial protective effect. This might simulate what happens during a day at the beach.
- 11 November 2008
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 24 (6) , 296-300
Sun protection factor persistence during a day with physical activity and bathing
Background/purpose: The persistence of sunscreens during a day with physical activity and bathing is often debated. We wished to examine the durability of the protection achieved by one sunscreen application.Methods: Seven areas were marked on the back of 24 volunteers. One area was phototested to determine UV sensitivity. Six areas were treated with either an organic or an inorganic sunscreen (2 mg/cm2). The participants performed physical activities, were exposed to a hot environment and bathing during 8 h and were phototested with ultraviolet‐B (UVB) radiation 30 min, 4 and 8 h after sunscreen application. The minimal erythema dose (MED) was determined 24 h after irradiation. The sun protection factor (SPF) was calculated, as MED on protected skin/MED on unprotected skin.Results: The SPFs of the inorganic and organic sunscreen, respectively, were reduced by 38% and 41% after 4 h and by 55% and 58% after 8 h.Conclusion: One application of either an inorganic or an organic sunscreen reduced the erythema caused by UVB during a day with physical activity and bathing. After 8 h the sunscreens still provided approximately 43% of the initial protective effect. This might simulate what happens during a day at the beach.
- 11 November 2008
- Published by Wiley in Experimental Dermatology
- Vol. 17 (12) , 992-997
TNF‐α stimulates Akt by a distinct aPKC‐dependent pathway in premalignant keratinocytes
Abstract: Tumor necrosis factor‐α (TNF‐α) is an important proinflammatory cytokine involved in the pathogenesis of inflammatory skin diseases and cutaneous squamous cell carcinoma. Some of these effects are mediated by the stimulatory effect of this cytokine on the Akt signalling pathway, which renders keratinocytes less susceptible to proapoptotic stimuli and enhances cell growth. We have recently shown that TNF‐α‐induced Akt activation may promote the early stages of skin cancer. In this work, we demonstrate that in the premalignant keratinocyte cell line HaCaT, TNF‐α activates Akt, ERK1/2 and p38. The specific peptide blocking the activity of the atypical protein kinase C (aPKC) species ζ and ι/λ abrogated the effects of TNF‐α on Akt and ERK1/2 but increased the activation of p38. The TNF‐α‐dependent phosphorylation of Akt–ERK1/2 was slightly decreased by NFκB inhibition and in the presence of p38 blockers. Akt/ERK signalling but not p38 activation was abolished in the presence of the iron chelator desferroxamine that blocks formation of hydroxyl (˙OH) radicals. Thus, the TNF‐α signalling in keratinocytes seems to bifurcate into an aPKC‐, NFkB‐ and ˙OH‐dependent pathway resulting in the activation of survival and mitogenic pathways mediated by Akt and ERK1/2, and a signalling pathway conveyed by p38 that contributes to Akt activation but is suppressed by aPKC. Our data may be utilized in the development of more selective anti‐TNF‐α therapeutic strategies.
- 11 November 2008
- Published by Wiley in Experimental Dermatology
- Vol. 17 (12) , 992-997
TNF‐α stimulates Akt by a distinct aPKC‐dependent pathway in premalignant keratinocytes
Abstract: Tumor necrosis factor‐α (TNF‐α) is an important proinflammatory cytokine involved in the pathogenesis of inflammatory skin diseases and cutaneous squamous cell carcinoma. Some of these effects are mediated by the stimulatory effect of this cytokine on the Akt signalling pathway, which renders keratinocytes less susceptible to proapoptotic stimuli and enhances cell growth. We have recently shown that TNF‐α‐induced Akt activation may promote the early stages of skin cancer. In this work, we demonstrate that in the premalignant keratinocyte cell line HaCaT, TNF‐α activates Akt, ERK1/2 and p38. The specific peptide blocking the activity of the atypical protein kinase C (aPKC) species ζ and ι/λ abrogated the effects of TNF‐α on Akt and ERK1/2 but increased the activation of p38. The TNF‐α‐dependent phosphorylation of Akt–ERK1/2 was slightly decreased by NFκB inhibition and in the presence of p38 blockers. Akt/ERK signalling but not p38 activation was abolished in the presence of the iron chelator desferroxamine that blocks formation of hydroxyl (˙OH) radicals. Thus, the TNF‐α signalling in keratinocytes seems to bifurcate into an aPKC‐, NFkB‐ and ˙OH‐dependent pathway resulting in the activation of survival and mitogenic pathways mediated by Akt and ERK1/2, and a signalling pathway conveyed by p38 that contributes to Akt activation but is suppressed by aPKC. Our data may be utilized in the development of more selective anti‐TNF‐α therapeutic strategies.
- 9 October 2008
- Published by Wiley in Experimental Dermatology
- Vol. 17 (11) , 933-938
Infliximab inhibits DNA repair in ultraviolet B‐irradiated premalignant keratinocytes
Abstract: Anti‐tumor necrosis factor‐α (TNFα) approaches are increasingly used in the therapy of autoimmune diseases. One of the safety concerns is the potential enhancement of skin carcinogenesis. The aim of this study was to investigate if the TNFα neutralizing antibody, infliximab, directly affects the cell cycle and DNA repair in premalignant human keratinocytes after ultraviolet‐B (UVB) irradiation. We found that infliximab‐treated cells exhibited an enhanced G2/M cell cycle arrest and increased apoptosis after 10–20 mJ/cm2 UVB. In spite of this, the level of cyclobutane pyrimidine dimers (CPD) in infliximab‐treated cells was significantly increased at both 24 and 48 h after irradiation with 10 mJ/cm2 UVB. As we have recently shown that protein kinase B/Akt is involved in the TNFα signalling pathway and promotes cell survival and skin carcinogenesis, we measured activatory phosphorylations of Akt (Ser‐473 and Thr‐308) and the signalling via related pathways Erk 1/2, p38 and p70‐S6K. Infliximab inhibited Akt and its downstream targets p70‐S6K and Erk 1/2, and stimulated p38 both in sham‐irradiated and UVB‐irradiated cells. In conclusion, despite the fact that infliximab blocks Akt and stimulates the G2/M checkpoint and apoptosis in UVB‐irradiated keratinocytes, the repair of CPD is impaired. It is conceivable that anti‐TNFα treatments may contribute to the accumulation of mutagenic lesions in the epidermis and enhance the early stages of skin carcinogenesis.
- 9 October 2008
- Published by Wiley in Experimental Dermatology
- Vol. 17 (11) , 933-938
Infliximab inhibits DNA repair in ultraviolet B‐irradiated premalignant keratinocytes
Abstract: Anti‐tumor necrosis factor‐α (TNFα) approaches are increasingly used in the therapy of autoimmune diseases. One of the safety concerns is the potential enhancement of skin carcinogenesis. The aim of this study was to investigate if the TNFα neutralizing antibody, infliximab, directly affects the cell cycle and DNA repair in premalignant human keratinocytes after ultraviolet‐B (UVB) irradiation. We found that infliximab‐treated cells exhibited an enhanced G2/M cell cycle arrest and increased apoptosis after 10–20 mJ/cm2 UVB. In spite of this, the level of cyclobutane pyrimidine dimers (CPD) in infliximab‐treated cells was significantly increased at both 24 and 48 h after irradiation with 10 mJ/cm2 UVB. As we have recently shown that protein kinase B/Akt is involved in the TNFα signalling pathway and promotes cell survival and skin carcinogenesis, we measured activatory phosphorylations of Akt (Ser‐473 and Thr‐308) and the signalling via related pathways Erk 1/2, p38 and p70‐S6K. Infliximab inhibited Akt and its downstream targets p70‐S6K and Erk 1/2, and stimulated p38 both in sham‐irradiated and UVB‐irradiated cells. In conclusion, despite the fact that infliximab blocks Akt and stimulates the G2/M checkpoint and apoptosis in UVB‐irradiated keratinocytes, the repair of CPD is impaired. It is conceivable that anti‐TNFα treatments may contribute to the accumulation of mutagenic lesions in the epidermis and enhance the early stages of skin carcinogenesis.
- Open Access
- 9 September 2008
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 8 (1) , 60
Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions
Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all industry-supported meta-analyses of drug-drug comparisons with those without industry support.
- 9 September 2008
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 8 (1) , 60
Open AccessIndustry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions
Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all industry-supported meta-analyses of drug-drug comparisons with those without industry support.
- 1 August 2008
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 128 (8) , 2069-2077
TNF-α Impairs the S-G2/M Cell Cycle Checkpoint and Cyclobutane Pyrimidine Dimer Repair in Premalignant Skin Cells: Role of the PI3K–Akt Pathway
- 1 August 2008
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 128 (8) , 2069-2077
TNF-α Impairs the S-G2/M Cell Cycle Checkpoint and Cyclobutane Pyrimidine Dimer Repair in Premalignant Skin Cells: Role of the PI3K–Akt Pathway
- 1 June 2008
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 144 (6) , 765-769
Synergistic Effect of Broad-Spectrum Sunscreens and Antihistamines in the Control of Idiopathic Solar Urticaria
Case Report from JAMA Dermatology — Synergistic Effect of Broad-Spectrum Sunscreens and Antihistamines in the Control of Idiopathic Solar Urticaria
- 1 June 2008
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 144 (6) , 765-769
Synergistic Effect of Broad-Spectrum Sunscreens and Antihistamines in the Control of Idiopathic Solar Urticaria
Case Report from JAMA Dermatology — Synergistic Effect of Broad-Spectrum Sunscreens and Antihistamines in the Control of Idiopathic Solar Urticaria
- 1 May 2008
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 144 (5) , 620-624
Topical Corticosteroids in the Treatment of Acute Sunburn
Research from JAMA Dermatology — Topical Corticosteroids in the Treatment of Acute Sunburn — A Randomized, Double-blind Clinical Trial
- 1 May 2008
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 144 (5) , 620-624
Topical Corticosteroids in the Treatment of Acute Sunburn
Research from JAMA Dermatology — Topical Corticosteroids in the Treatment of Acute Sunburn — A Randomized, Double-blind Clinical Trial